Des-g-carboxy Prothrombin (DCP)

Sample type: Serum

Other names: DCP, Des-gamma-carboxy Prothrombin, PIVKA-II, Protein Induced by Vitamin K Absence

Optimal result: 0 – 7.5 ng/mL

Elevated levels of Des-γ-carboxy Prothrombin (DCP) in a blood panel can be a significant indicator, particularly in the context of liver health. When DCP levels are high, it usually suggests a disruption in the liver's ability to fully process prothrombin, a protein crucial for blood clotting. This disruption is often due to a deficiency in vitamin K or a malfunction in the liver's carboxylation system, which can be associated with liver diseases like chronic hepatitis, cirrhosis, or more concerning, hepatocellular carcinoma (HCC), a type of liver cancer.

It's important to understand that elevated DCP levels are not a definitive diagnosis of HCC or any other specific liver condition on their own. They signal the need for further diagnostic evaluation, which typically involves a combination of imaging tests (like ultrasound, CT scans, or MRIs), additional blood tests, and sometimes a liver biopsy. These comprehensive assessments help determine the underlying cause of the elevated DCP levels.

If the cause is found to be a liver condition such as HCC, the treatment options vary depending on the stage and severity of the disease. Early-stage HCC might be treated with surgical resection (removing the tumor), liver transplant (in eligible patients), or local therapies like ablation (destroying the tumor with heat or cold) or embolization (blocking the blood supply to the tumor). For more advanced HCC, treatments may include targeted therapies (drugs that specifically target cancer cells), immunotherapy (which helps your immune system fight cancer), or chemotherapy.

In cases where elevated DCP levels are linked to non-cancerous liver diseases, treatment focuses on managing the underlying condition. This could involve lifestyle changes (like diet and exercise for fatty liver disease), medication (for chronic hepatitis), or other interventions tailored to the specific liver condition.

It's crucial for individuals with elevated DCP levels to work closely with their healthcare provider for an accurate diagnosis and appropriate treatment plan. Each case is unique, and the management strategy should be personalized based on the individual's overall health, the specifics of their liver condition, and other relevant factors.

Des-γ-carboxy Prothrombin (DCP), also known as Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), is a unique and clinically significant biomarker often included in blood panels, particularly in the context of liver health and hepatocellular carcinoma (HCC) screening. DCP is an abnormal form of prothrombin, a vital protein for blood coagulation, produced in the liver. It arises when there is a deficiency of vitamin K or a dysfunction in the carboxylation system within the liver cells. In healthy individuals, prothrombin is fully carboxylated in the presence of vitamin K, allowing it to play its crucial role in the coagulation cascade. However, in certain pathological conditions, particularly in the presence of hepatic malignancies such as HCC, the capacity for complete carboxylation is impaired, leading to the release of partially carboxylated or completely uncarboxylated prothrombin, identified as DCP.

Des-γ-carboxy Prothrombin (DCP), also known as Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), is a unique and clinically significant biomarker often included in blood panels, particularly in the context of liver health and hepatocellular carcinoma (HCC) screening. DCP is an abnormal form of prothrombin, a vital protein for blood coagulation, produced in the liver. It arises when there is a deficiency of vitamin K or a dysfunction in the carboxylation system within the liver cells. In healthy individuals, prothrombin is fully carboxylated in the presence of vitamin K, allowing it to play its crucial role in the coagulation cascade. However, in certain pathological conditions, particularly in the presence of hepatic malignancies such as HCC, the capacity for complete carboxylation is impaired, leading to the release of partially carboxylated or completely uncarboxylated prothrombin, identified as DCP.

The clinical importance of DCP lies in its utility as a tumor marker for the early detection and monitoring of HCC. Studies have shown that DCP levels are significantly elevated in many patients with HCC, often correlating with tumor size, stage, and prognosis. This makes DCP a valuable tool in the diagnostic process, particularly in conjunction with other tumor markers like alpha-fetoprotein (AFP) and imaging studies. DCP's sensitivity and specificity vary based on the cutoff values used and the population being studied, but it is generally regarded as a more specific marker for HCC than AFP, especially in patients with cirrhosis, where AFP levels may be elevated without the presence of HCC.

Additionally, DCP measurements can be useful in monitoring the treatment response and recurrence in patients undergoing therapy for HCC. An increasing trend in DCP levels may indicate tumor progression or recurrence, while a decrease might suggest a favorable response to treatment.

However, it's important to note that elevated DCP levels are not exclusively associated with HCC. They can also be observed in other liver diseases, such as chronic hepatitis and cirrhosis, or in conditions that affect vitamin K metabolism. Therefore, DCP should be interpreted in the context of a comprehensive clinical evaluation and in conjunction with other diagnostic modalities.

Des-g-carboxy Prothrombin (DCP)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Des-g-carboxy Prothrombin (DCP) — 10,000+ markers explained
One Des-g-carboxy Prothrombin (DCP) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro